Trial Profile
A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 25 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 25 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.